UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
City of Hope |
|
Torque Therapeutics, Inc. |
Cancer - Lymphoma |
TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas |
Recruiting |
|
UCSF |
|
CIRM & NHLBI |
Severe sickle cell disease |
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease |
Active, not recruiting |
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 |
No longer active |
|
UCSD |
|
Mesoblast |
Heart Failure |
The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure |
No longer active |
|
UCLA |
|
UCLA |
Cancer |
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) |
No longer active |
|
City of Hope |
|
Atara Bio. |
Cancer - Nasopharyngeal Carcinoma |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
No longer active |
|
UCSD |
|
Discgenics |
Degenerative Disc Disease |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
No longer active |
|
UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) |
Active, not recruiting |
|
UCI |
|
SanBio |
Stroke |
Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke |
No longer active |
|
UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Active, not recruiting |
|
UCSD |
|
UCSD |
Cancer - Breast |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Active, not recruiting |
|
City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) |
Recruiting |
|
City of Hope |
|
Juno Therapeutics |
Cancer - Myeloma |
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) |
Recruiting |
|
City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) |
No longer active |
|
UCI |
|
Stratetech |
Burn wounds |
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
No longer active |
|
UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC |
Recruiting |
|
City of Hope & UCLA |
|
City of Hope |
HIV/AIDS |
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients |
No longer active |
|
UCSD |
|
Neuralstem |
Spinal Cord Injury |
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI |
Recruiting |
|
UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
City of Hope |
|
City of Hope |
Sickle Cell Disease |
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) |
Recruiting |
|
UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
UCSF & UCSD & CIRM |
|
CIRM |
ARDS/COVID |
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) |
No longer active |
|
City of Hope |
|
Glaxo Smith Kline (GSK) |
Cancer - Lung |
Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab |
No longer active |
|
UC Davis |
|
Pluristem Ltd. |
Muscle Injury - hip fracture |
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty |
Recruiting |
|
UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
UCSF |
|
Cellectis, SA |
Multiple Myeloma |
Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu |
No longer active |
|
UCSF |
|
Allo Vir, Inc. |
BK Viremia in Kidney Transplant Recipients |
Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients |
No longer active |
|
UC Davis |
|
Nohla Therapeutics |
Cancer – Leukemia |
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML |
No longer active |
|
UC Davis |
|
AlloVir |
Kidney transplant |
Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with |
No longer active |
|
UC Davis |
|
UC Davis/CIRM |
Spina bifida |
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele |
Recruiting |
|
UC Davis |
|
Cabaletta |
Pemphigus Vulgaris |
Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris |
Recruiting |
|
UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) |
No longer active |
|
UC Davis |
|
Capricor Therapeutics |
Duchenne Muscular Dystrophy |
Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE) |
Recruiting |
|
UCSF & UC Davis |
|
Poseida Therapeutics, Inc. |
Multiple Myeloma |
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) |
No longer active |
|
UCI |
|
Brain Neurotherapy Bio |
Parkinson's |
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease |
Active, not recruiting |
|
City of Hope |
|
Adaptimmune |
Cancer - Myeloma |
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma |
Recruiting |
|
UC Davis |
|
Atara Bio. |
EBV-PTLD |
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
No longer active |
|
UCSF & UC Davis |
|
|
COVID-19/ARDS |
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
No longer active |
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma |
Recruiting |
|
City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Long-Term Follow-up Study for Patients Previously Treated With JCAR015 |
No longer active |
|
UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
Long term follow-up study for patients administered CLBR001 , a CAR-T cell |
No longer active |
|
UCSF |
|
UCSF |
Blood Disorder - Alpha Thalassemia Major |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
Recruiting |
|
City of Hope |
|
City of Hope |
Cancer - Brain |
HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases |
Recruiting |
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma |
Recruiting |
|
City of Hope |
|
City of Hope |
Cancer - Leukemia |
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
Recruiting |
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas |
Active, not recruiting |
|